
    
      This will be a single centre, combined IV and oral single dose, open-label study in healthy
      male volunteers.

      Each subject will receive the following formulations on a single study day:

        1. Regimen A: A single 10 mL oral dose of 250 mg SRT2104 delivered as a suspension
           formulation;

        2. Regimen B: A single intravenous dose of 10 mL containing 100 Âµg (not more than 250 nCi,
           9.25 kBq) Carbon-14 radio-labeled SRT2104 , administered by IV infusion over 15 minutes,
           starting 2 hours and 45 minutes after the oral dose.
    
  